Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Blood|February 27, 2015
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, et al.
Blood Neoplasia|June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasmZhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.
Haematologica|May 19, 2018
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34<sup>+</sup>CD123<sup>+</sup> cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donorsRajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, et al.
Annals of Hematology|July 2, 2026
Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024)Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
American Journal of Respiratory and Critical Care Medicine|October 9, 2014
Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trialYahya Shehabi, Martin Sterba, Peter Maxwell Garrett, et al.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Pageof 6